Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: polyarticular JIA

FDA Approves New Biosimilar for Adult & Pediatric Arthritis

Michele B. Kaufman, PharmD, BCGP  |  November 6, 2023

This year, tocilizumab biosimilars have been approved to treat adult and pediatric patients with rheumatic disease, including rheumatoid arthritis, juvenile idiopathic arthritis and more, in both Europe and the U.S.

Filed under:Biologics/DMARDsDrug UpdatesPediatric ConditionsRheumatoid Arthritis Tagged with:BiosimilarstocilizumabU.S. Food and Drug Administration (FDA)

FDA Provides 2020 Rheumatology Drug Update

Susan Bernstein  |  December 17, 2020

Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2020FDAmeeting reportsU.S. Food and Drug Administration (FDA)

The 2020 ACR Review Course: Key Issues Rheumatologists Face

Jason Liebowitz, MD, FACR  |  December 17, 2020

The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone DisordersPediatric ConditionsVasculitis Tagged with:ACR Convergence 2020liver diseasemeeting reportsOsteoporosisPediatricpregnancyVasculitis

2020 Pediatric Rheumatology Research in Review

Carina Stanton  |  November 24, 2020

ACR CONVERGENCE 2020—This has been a busy year for research publications covering a number of pediatric rheumatic diseases, including the emerging multi-system inflammatory syndrome (MIS-C) associated with SARS CoV-2. Despite the many challenges brought about by the COVID-19 pandemic, a healthy collection of publications covering a wide range of pediatric rheumatology research topics were published…

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic ConditionsPediatric ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:COVID-19geneticshealth disparitiesJuvenile Arthritis (JIA)Kawasaki diseaseMultisystem Inflammatory Syndrome in Children (MIS-C)Pediatric Rheum

3 Ways to Advance the Med-Peds Role in Rheumatology

Carina Stanton  |  April 27, 2020

Research into training and careers for Med-Peds—internal medicine-pediatrics trained rheumatologists–will help pinpoint how this unique specialty can support patient needs and address rheumatology workforce shortages…

Filed under:Career DevelopmentEducation & TrainingProfessional Topics Tagged with:adult rheumatologistCareerMed-Pedspediatric rheumatologist

The 2019 ACR Award Winners & Distinguished Fellows

Carol Patton  |  December 18, 2019

ATLANTA—Every year at its Annual Meeting, the ACR recognizes its members’ outstanding contributions to the field of rheumatology through an awards program. The ACR is proud to announce 20 award recipients for 2019, honored for their accomplishments as clinicians, instructors or researchers who have helped advance rheumatology, for their commitment to inspire others to enter…

Filed under:AwardsFrom the CollegeProfessional Topics Tagged with:2019 ACR/ARP Annual MeetingDr. Alfred E. DenioDr. Ali Duarte-GarciaDr. Amr H. SawalhaDr. Brian NolanDr. Bruce CronsteinDr. Dana DiRenzoDr. J. Timothy HarringtonDr. Jean LiewDr. John P. AtkinsonDr. Katherine P. LiaoDr. Marcy B. BolsterDr. Mazen NasrallahDr. Michael A. PaleyDr. Natalie RosenwasserDr. Patricia KatzDr. Polly FergusonDr. Rebecca HabermanDr. Sarah ChenDr. Susan ManziJonathan TL Cheah

An Overview of Pediatric, Noninfectious Uveitis

Joseph McDonald, MD, Virginia Miraldi Utz, MD, & Sheila T. Angeles-Han, MD, MS  |  October 18, 2018

Uveitis is an inflammation of the uvea, which comprises the iris, ciliary body and choroid. Uveitis can lead to ocular damage and complete visual loss. Noninfectious etiologies for uveitis are the most common in the U.S.1 The estimated incidence of uveitis ranges from 25–52 per 100,000 in adults and five per 100,000 in children. The…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Juvenile Arthritis (JIA)Uveitis

Adalimumab Appears Safe for Treating Pediatric Patients with Autoimmune Disease

Reuters Staff  |  August 8, 2018

NEW YORK (Reuters Health)—Adalimumab appears to be safe for treating pediatric patients with polyarticular juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA), psoriasis and Crohn’s disease (CD), according to data from company-sponsored clinical trials. Adalimumab is an anti-tumor necrosis factor monoclonal antibody with demonstrated efficacy in these conditions, but pediatric safety data remains limited. Dr. Gerd…

Filed under:ConditionsDrug Updates Tagged with:adalimumabCrohn's disease (CD)enthesitis-related arthritis (ERA)polyarticular juvenile idiopathic arthritis (JIA)Psoriasis

Alendronate May Provide Cardiovascular Benefits; Plus FDA Approves Subcutaneous Tocilizumab

Michele B. Kaufman, PharmD, BCGP  |  May 28, 2018

New research has linked alendronate to reduced cardiovascular death in hip fracture patients…

Filed under:Drug Updates Tagged with:alendronatecardiovascularFDAFractureship fractureJuvenile Arthritis (JIA)polyarticular juvenile idiopathic arthritistocilizumabU.S. Food and Drug Administration (FDA)

Experts Discuss the Latest Precision Medicine Research

Susan Bernstein  |  February 18, 2018

SAN DIEGO—In just two decades, precision medicine has gone from futuristic concept to realistic toolbox for clinical physicians. At the 2017 ACR Clinical Research Conference on Nov. 3, the Precision Medicine in Rheumatic Diseases: Hopes and Challenges lecture featured rheumatologists and experts on genetics, genomics, pharmaco­genetics and big data who spoke about the latest research…

Filed under:Meeting ReportsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ACR/ARHP Annual MeetingArthritisbig dataGenetic researchgenomicsLupusPrecision MedicineRheumatoid arthritis

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences